This Insmed Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
"Don't sell if prices don't drop!" Trump enforces a mandatory minimum drug price for developed countries, but a lawsuit battle may be "reenacted".
① An executive order signed on the 12th of October, USA time, requires that the payment price of pharmaceuticals in the USA be forcibly anchored to the lowest level of other developed countries within 30 days; ② There is strong opposition within the USA, and industry experts estimate that a legal battle is about to "replay"; ③ As the market-oriented USA begins to wield the big stick of administrative pricing, the underlying rules of the game for Innovative Drugs have quietly been rewritten.
Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today
The "Most-Favored-Nation Pricing" policy for Trump Medicine has been issued: benchmarked against developed countries, complete the Quote within 30 days.
① This policy aims to align prescription drug pricing in the USA with that of "Other developed countries". Trump has requested that the Quote be completed within 30 days; ② The scope of affected Pharmaceuticals is still unclear, and the White House has stated that the government will pay special attention to drugs that have the "largest price differences and highest spending"; ③ Trump had implemented a similar policy before the end of his last term, but it was blocked by the courts and ultimately fell through.
Analyst Expectations For Insmed's Future
Alnylam Pharma To Present Latest Data From Flagship Transthyretin Amyloidosis Franchise At Upcoming Heart Failure 2025 Congress
United Therapeutics Corporation Filed A Complaint On May 9, 2025, In The U.S. District Court For The Middle District Of North Carolina Against Liquidia Alleging Infringement Of U.S. Patent No. 11,357,782.
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'
Insmed Analyst Ratings
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
8 Analysts Have This To Say About Natera
Natera Analyst Ratings
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Natera Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Sales Guidance Above Estimates.
Natera GAAP EPS of -$0.50 Beats by $0.12, Revenue of $501.8M Beats by $55.13M
Insmed Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Earnings and Reaffirmed Full-year Guidance Below Estimates.
Natera To Present Multiple Datasets In Breast Cancer Together With Collaborators At 2025 ESMO Breast Cancer Annual Congress In Munich
Here Are the Major Earnings After the Close Today
Here Are the Major Earnings Before the Open Tomorrow
Preview: Natera's Earnings